Retagliptin
Chemical compound
From Wikipedia, the free encyclopedia
Retagliptin is a DPP-4 inhibitor studied for the treatment of type 2 diabetes.[1][2][3]
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H18F6N4O3 |
| Molar mass | 464.368 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
In 2023, it was approved in China by the National Medical Products Administration for blood glucose control for adult patients with type 2 diabetes.[4]